GoAI
Get started
KALA BIO, Inc. logo

KALA BIO, Inc.

KALA

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$0.8195

−$0.0006 · -0.07%

Aug 24, 10:22 AM ETData delayed

KALA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

28

Weakening

Sentiment

39

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Avi Minkowitz
Listed since
Jul 20, 2017
Employees
6

Market position

Day range

Current $0.8195

52-week range

Current $0.8195

Open
$0.82
Previous close
$0.8201
Volume
31.65K
0.26× average
Average volume
119.62K
Average daily volume
Market cap
15.85M USD
Beta
-2.28
Market reference 1
50-day average
$1.4081
-41.80% below average
200-day average
$15.3858
-94.67% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
218.97M USD
P/E (TTM)
-0.04×
P/B (TTM)
6.72×
P/S (TTM)
0×
EV / EBITDA
-9.36×
Earnings yield
-11.91%
Free cash flow yield
-14.12%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-385.65%
Return on assets
-284.30%
Return on invested capital
-559.76%

Financial health

Debt / equity
0×
Current ratio
3.81×
Altman Z-score
-87.99
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends279%-583%-1444%-2306%Gross margin, FY2021: 63.55%Gross margin, FY2022: 34.22%Operating margin, FY2021: -973.60%Operating margin, FY2022: -2090.34%Net margin, FY2021: -1268.73%Net margin, FY2022: -1151.64%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.55%. Gross margin FY2022 34.22%. Operating margin FY2021 -973.60%. Operating margin FY2022 -2090.34%. Net margin FY2021 -1268.73%. Net margin FY2022 -1151.64%.

Income trends

Revenue

3.89M USD-65.37%

Operating income

−39.16M USD+3.15%

Net income

−26.98M USD+29.94%
Income trends across reported periods26.62M USD−34.91M USD−96.45M USD−157.99M USDRevenue, FY2021: 11.24M USDRevenue, FY2022: 3.89M USDOperating income, FY2021: −109.43M USDOperating income, FY2022: −81.36M USDOperating income, FY2023: −39.15M USDOperating income, FY2024: −40.43M USDOperating income, FY2025: −39.16M USDNet income, FY2021: −142.61M USDNet income, FY2022: −44.82M USDNet income, FY2023: −42.2M USDNet income, FY2024: −38.51M USDNet income, FY2025: −26.98M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 11.24M USD. Revenue FY2022 3.89M USD. Operating income FY2021 −109.43M USD. Operating income FY2022 −81.36M USD. Operating income FY2023 −39.15M USD. Operating income FY2024 −40.43M USD. Operating income FY2025 −39.16M USD. Net income FY2021 −142.61M USD. Net income FY2022 −44.82M USD. Net income FY2023 −42.2M USD. Net income FY2024 −38.51M USD. Net income FY2025 −26.98M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———3.89M USD11.24M USD
Cost of goods sold—259K USD303K USD2.56M USD4.1M USD
Gross profit—−259K USD−303K USD1.33M USD7.14M USD
Research and development18.78M USD21.84M USD18.59M USD17.65M USD11.52M USD
Selling, general, and administrative23.63M USD18.34M USD20.26M USD65.04M USD105.06M USD
Operating expenses39.16M USD40.18M USD38.85M USD82.69M USD116.58M USD
Interest income1.14M USD2.06M USD2.71M USD664K USD104K USD
Interest expense3.28M USD5.78M USD5.81M USD7.27M USD8.38M USD
Depreciation and amortization317K USD259K USD303K USD860K USD2.27M USD
Operating income−39.16M USD−40.43M USD−39.15M USD−81.36M USD−109.43M USD
Net income−26.98M USD−38.51M USD−42.2M USD−44.82M USD−142.61M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
-308.52%
11 comparable reports
Latest EPS result
-21.32
Estimate -6 · Miss by 255.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates9.21-34.9-79.01-123.13Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ2 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -87, estimate -114, surprise +23.68%, Beat. Q2 2025, reported May 14, 2025: actual -70.5, estimate -101.5, surprise +30.54%, Beat. Q3 2025, reported Aug 8, 2025: actual -85.5, estimate -91, surprise +6.04%, Beat. Q4 2025, reported Nov 19, 2025: actual -1.07, estimate -50.5, surprise +97.88%, Beat. Q2 2026, reported Apr 15, 2026: actual 0.084, estimate -16, surprise +100.53%, Beat. Q2 2026, reported May 15, 2026: actual -0.14, estimate -8.5, surprise +98.35%, Beat. Q3 2026, reported Aug 19, 2026: actual -21.32, estimate -6, surprise -255.33%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate -6, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.25

2126.97% upside
Past 12 months12-month forecastHigh $35.00Average $18.25Low $1.50

Rating distribution

11 ratings
Strong buy00%
Buy436%
Hold655%
Sell19%
Strong sell00%

Recent analyst actions

5 institutions
MizuhodowngradeOutperformNeutral
Ladenburg ThalmanndowngradeBuyNeutral
H.C. WainwrightdowngradeBuyNeutral

KALA news

Corporate actions

Corporate action history

Stock split

Effective May 11, 2026

1:50

Stock split

Effective Oct 21, 2022

1:50

Stock split

Effective Aug 26, 2022

2:1

KALA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding KALA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
166.77K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$244.04-0.61%

Continue in GoAI

Research KALA

research.disclaimer